XML 32 R26.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Summary of Segment Profit or Loss, Including Significant Expenses | The table below is a summary of the segment profit or loss, including significant expenses, in thousands:
| Three Months Ended September 30, |  | Nine Months Ended September 30, |
| 2025 |  |  | 2024 |  | 2025 |  |  | 2024 |
Collaboration revenue | $ | 20,750 |  |  | $ | — |  | $ | 50,146 |  |  | $ | — |
Less: |  |  |  |  |  |  |  |  |  |
Ziftomenib-related costs |  | 40,320 |  |  |  | 18,993 |  |  | 107,851 |  |  |  | 52,335 |
Darlifarnib (KO-2806)-related costs |  | 8,494 |  |  |  | 5,178 |  |  | 19,871 |  |  |  | 13,026 |
Tipifarnib-related costs |  | 443 |  |  |  | 721 |  |  | 2,578 |  |  |  | 3,560 |
Discovery stage program-related costs |  | 1,744 |  |  |  | 1,769 |  |  | 5,323 |  |  |  | 4,950 |
Research and development personnel costs and other expenses |  | 13,695 |  |  |  | 11,474 |  |  | 41,790 |  |  |  | 32,611 |
Share-based compensation expense |  | 10,965 |  |  |  | 8,324 |  |  | 25,756 |  |  |  | 25,266 |
Other segment expenses(1) |  | 25,086 |  |  |  | 13,425 |  |  | 64,340 |  |  |  | 38,992 |
Total operating expenses |  | 100,747 |  |  |  | 59,884 |  |  | 267,509 |  |  |  | 170,740 |
Other income (expenses) |  |  |  |  |  |  |  |  |  |
Interest and other income |  | 6,274 |  |  |  | 5,892 |  |  | 21,088 |  |  |  | 17,190 |
Interest expense |  | (393 | ) |  |  | (412 | ) |  | (1,166 | ) |  |  | (1,216 | )
Income tax expense |  | — |  |  |  | — |  |  | (226 | ) |  |  | — |
Segment and net loss | $ | (74,116 | ) |  | $ | (54,404 | ) | $ | (197,667 | ) |  | $ | (154,766 | )
(1) Other segment expenses are comprised of general and administrative expenses, excluding share-based compensation expense, which is shown separately.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration